Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Cancer Female × palbociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 119 Neoplasm Metastasis 20 Neoplasms 16 Sarcoma 10 Ovarian Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 8 Pancreatic Neoplasms 8 Carcinoma, Non-Small-Cell Lung 7 Endometrial Neoplasms 6 Colorectal Neoplasms 6 Prostatic Neoplasms 5 Melanoma 5 Lymphoma, Non-Hodgkin 5 Head and Neck Neoplasms 5 Sarcoma, Ewing 4 Recurrence 4 Multiple Myeloma 4 Medulloblastoma 4 Lung Neoplasms 4 Carcinoma, Renal Cell 4 Breast Diseases 4 Triple Negative Breast Neoplasms 3 Rhabdomyosarcoma 3 Rhabdoid Tumor 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Osteosarcoma 3 Neuroblastoma 3 Liposarcoma 3 Leukemia, Myeloid, Acute 3 Glioblastoma 3

Interventions

Tamoxifen 3 Exercise 3 pyrotinib 2 abemaciclib 2 Paclitaxel 2 Metformin 2 Cyclophosphamide 2 Capecitabine 2 Bupivacaine 2 pembrolizumab 1 pegylated granulocyte colony-stimulating factor 1 pegfilgrastim 1 palbociclib 1 iniparib 1 exemestane 1 durvalumab 1 darolutamide 1 Yoga 1 Waiting Lists 1 Vitamin D 1 Tretinoin 1 Trastuzumab 1 Tocopherols 1 Thioctic Acid 1 Standard of Care 1 Sodium Chloride 1 Self-Help Groups 1 Saline Solution 1 Ropivacaine 1 Radiofrequency Ablation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03065621 2023-04-19

NeoRHEA

Jules Bordet Institute

Phase 2 Completed

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡